ISBN : 978-93-85073-24-3 106. L. J. Kirmayer, J. M. Robbins, M. Dworkind, Am. J. Psychiatry., 150, 734– 741, 1993. 107. P. D. Gerber, J. E. Barrett, J. A. Barrett, J. Gen. Intern. Med., 7, 170–173, 1992. 108. M. Posse, T. Hallstrom, Acta. Psychiatr. Scand., 98, 187–192, 1998. 109. K. Barkow, R. Heun, T. B. Ustun, Eur. Arch. Psychiatry. Clin. Neurosci., 251, 21–26, 2001. 110. G. E. Simon, M. Von Korff, M. Piccinelli, N. Engl. J. Med., 341, 1329–1335, 1999. 111. K. Kroenke, R. K. Price, Arch. Intern. Med., 153, 2474–2480, 1993. 112. E. H. F. Wong, M. S. Sonders, S. G. Amara, Biol. Psychiat., 47, 818-829, 2000. 113. T. DeBoer, G. Maura, M. Raiteri, Neuropharmacol., 27, 399-408, 1988. 114. J. A. Ascher, J. O. Cole, J. N Colin, J. Clin. Psychiat., 56, 395-401, 1995. 115. M. B. Segal, Cell. Mol. Neurobiol., 20, 183-196, 2000. 116. W. M. Pardridge, "Brain Drug Targeting, The future of Brain Drug Development" Cambridge, U. K., Cambridge University Press, 2001. 117. W. M. Pardridge, Mol. Interv., 3, 90-105, 2003. 118. A. Martin, P. Bustamanate, A. H. C. Chun, “Physical Pharmacy” B. I. Wavely Pvt. Ltd, New Delhi, 4, 223, 1994. 119. A. Osol, (eds.) in: “Remington’s Pharmaceutical Sciences” Mack Publishing Company, Eastern Pennsylvania, 18, 203, 1990. 120. C. Neuberg, Biochem. J. Pharm., 75, 577, 1989. 121. D. Jennifer, K. Johannes, Pharmaceutical Dissolution Testing; Taylor & Francis, Boca Raton, FL, 2005. 122. J. B. Dressman, G. L. Amidon, C. Reppas, V. P. Shah, Pharm. Res., 15, 11-22, 1998. 123. D. Horter, J. B. Dressman, Adv. Drug Deliv. Rev., 46, 75-87, 2001. 124. C. D. Melia, Crit. Rev. Ther. Drug, 8, 395-421, 1990. 125. H. Lapidus, N. G. Lordi, J. Pharm. Sci., 57, 1292-1301, 1968. 22
28 Publizr Home